NCT07041099

A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease

A Phase 1b, Open-Label Study of CLN-978 for the Treatment of Active, Moderate to Severe Sjogren's Disease

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 36 (estimated)
• Sponsor: Cullinan Therapeutics Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A phase 1b, open-label study of CLN-978 administered subcutaneously in patients with active, moderate to severe Sjogren's Disease.

Conditions

• Sjögren
• Sjogren Disease
• Sjogren's Syndrome

Interventions

Type	Name	Description
DRUG	CLN-978	Specified dose on specified days

Timeline

• Start date: 2025-10-01
• Primary completion: 2028-03-15
• Completion: 2029-03-15
• First posted: 2025-06-27
• Last updated: 2026-03-23

Locations

11 sites across 4 countries: United States, France, Germany, Italy

Regulatory

• FDA-regulated drug study